Search for a trial

Multi-centre, randomized, double-blind, parallel-group study evaluating the effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder once daily compared with Vilanterol (VI) Inhalation Powder Once Daily on Bone Mineral Density (BMD) in subjects with Chronic Obstructive Pulmonary Disease (COPD) (HZC102972)

Effect on bone mineral density.

A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared with tiotropium on Chronic Obstructive Pulmonary Disease (COPD) exacerbation in patients with severe to very severe COPD.

The aim of this study is to demonstrate that once daily treatment with tiotropium + olodaterol fixed dose combination will reduce the number of exacerbations over tiotropium 5 µg monotherapy.A secondary aim of the study is an assessment of a…

A Sequential Two Phase Multicenter, Randomized Study to Optimize Dose Selection and Evaluate Safety After Treatment with the Holaira* Lung Denervation System in Patients with Moderate to Severe COPD.

Phase A: To evaluate the safety and feasibility of the Holaira System at two energy levels in order to establish the optimal energy dose.Phase 2: To compare the safety and feasibility outcomes between the Holaira System vs. a Sham-control group…

Sinusoidal Compared With Constant Work Rate High Intensity Exercise Training In COPD Patients With Ventilatory Limitation

The primary outcome measure will be comparison of improvement in endurance of a work rate initially eliciting exercise limitation after 6 minutes (calculated from the power-duration relationship before and after training). We will also compare…

Prevention of atelectasis in the preoxygenation phase: comparison of two different oxygenation strategies

To assess if preoxygenation with 100% O2 or preoxygenation with 100% O2 and PEEP are different with respect to the development of atelectasis as determined by lung computed tomography.

A 52-week treatment, multi-center, randomized, doubleblind, double dummy, parallel-group, active controlled study to compare the effect of QVA149 (indacaterol maleate / glycopyrronium bromide) with salmeterol/fluticasone on the rate of exacerbations in subjects with moderate to very severe COPD (CQVA149A2318)

Primary objective: To demonstrate that QVA149 (110/50 *g o.d.) is at least non-inferior to salmeterol/fluticasone (50/500 *g b.i.d.) in terms of rate of COPD exacerbations.Secondary objectives: Superiority in terms of exacerbation rate. Time to…

A randomized, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution delivered by the Respimat® Inhaler with Tiotropium inhalation capsules 18 µg delivered by the HandiHaler®.

To compare the efficacy and safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution delivered by the Respimat® Inhaler with Tiotropium inhalation capsules 18 µg delivered by the HandiHaler®.

The effects of plant stanols on the immune function of asthma patients

The major research objective is to prove that the consumption of plant stanol ester enriched yogurts can improve immune function in vivo in asthma patients

A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 µg / 5 µg; 5 µg / 5 µg) (delivered by the RESPIMAT) compared with the individual components (2.5 µg and 5 µg tiotropium, 5 µg olodaterol) (delivered by the RESPIMAT) in patients with Chronic Obstructive Pulmonary Disease (COPD) [TOnadoTM 1]

The objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium plus olodaterol fixed dose combination compared with the individual components tiotropium and olodaterol (delivered by…

A 64-week treatment, multi-center, randomized, double-blind, parallel-group, active controlled study to evaluate the effect of QVA149 (110/50 *g o.d.) vs NVA237 (50 *g o.d.) and open-label tiotropium (18 *g o.d.) on COPD exacerbations in patients with severe to very severe chronic obstructive pulmonary disease (COPD) (CQVA149A2304)

Primary objective: To demonstrate that QVA149 (110/50 *g o.d.) is superior to NVA237 (50 *g o.d.) with regard to the rate of moderate to severe COPD exacerbations during 64 weeks of treatmentSecondary objectives: To demonstrate that QVA149 (110/50 *…

Internet-based treatment of depressive symptoms in patients with tumors inside or outside of the central nervous system.

The primary study objectives are: (1) to determine whether an internet-based guided self-help intervention is effective in reducing symptoms of depression in glioma patients; (2) to determine the impact of the intervention on the HRQOL of both…

SAS115358, a 6-month safety and benefit study of inhaled fluticasone
propionate/ salmeterol combination versus inhaled fluticasone
propionate in the treatment of 6,200 pediatric subjects 4-11 years
old with persistent asthma.

The primary objective is to evaluate whether the addition of a LABA to an ICS (FSC) therapy is non-inferior in terms of risk of serious asthma-related events (asthma-related hospitalizations, endotracheal intubations, and deaths) compared with ICS…

A study to compare the efficacy and safety of once daily QVA149 vs. the once daily concurrent administration of QAB149 plus NVA237 in patients with moderate to severe chronic obstructive pulmonary disease (CQVA149A2326)

Primary objective: To evaluate the non-inferiority of QVA149 110/50 µg qd as compared to concurrentadministration of QAB149 150 µg qd plus NVA237 50 µg qd in terms of its effect on trough FEV1 (mean of 23 h 15 min and 23 h 45 min post-dose)…

A Randomised, Double Blind, Double Dummy, Parallel Group Study Comparing UMEC/VI (A Fixed Combination Of Umeclidinium and Vilanterol) With Tiotropium In COPD Subjects Who Continue To Have Symptoms on Tiotropium (DB2116960)

Efficacy and safety.

DB2116134: A randomized, multi-center, double-blind, double-dummy, parallel group study to evaluate the efficacy and safety of umeclidinium/vilanterol compared with fluticasone propionate/salmeterol over 12 weeks in subjects with COPD

Efficacy and safety.

Lung aeration measured by EIT after a lung recruitment manoeuvre directly after intubation in mechanically ventilated critically ill patients

The primary objective of this study is to compare the effect of a standard and early RM in newly intubated critically ill patients. The secondary objective is to determine the effect of an early RM on cardiac function. We hypothesize an early RM to…

Prevention of passive smoking exposure in children with a high risk on asthma: the results of a individualized, tailored intervention.

The current proposal aims at testing an innovative, implementable, effective intervention strategy towards stopping of passive smoke exposure in children at risk for asthma.

SAS115359, a Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects with Asthma.

The primary objective of the study is to evaluate whether the addition of LABA to ICS therapy (FSC) is non-inferior to ICS therapy alone (FP) in terms of the risk of serious asthma related events (asthma-related hospitalization, endotracheal…

Optimizing COPD care in primary care: going for Silver or for Gold?

To evaluate a result oriented smoking cessation program in which treatment goals are signed up in a doctor-patient contract.

Healt status guided COPD (March)

We hypothesize that a treatment algorithm that is based on a simple validated measure of health status (CCQ) improves quality of life (as measured on a separate scale) and other classical COPD outcome measurement parameters such as exacerbation…